NASDAQ:INDP Indaptus Therapeutics (INDP) Stock Price, News & Analysis → The only AI company to buy (From Porter & Company) (Ad) Free INDP Stock Alerts $2.37 -0.11 (-4.44%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$2.35▼$2.5050-Day Range$2.01▼$2.7752-Week Range$1.56▼$4.08Volume17,876 shsAverage Volume23,276 shsMarket Capitalization$20.24 millionP/E RatioN/ADividend YieldN/APrice Target$12.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Indaptus Therapeutics alerts: Email Address Indaptus Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside406.3% Upside$12.00 Price TargetShort InterestHealthy0.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.03Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.83) to ($1.44) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.99 out of 5 starsMedical Sector391st out of 924 stocksPharmaceutical Preparations Industry179th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingIndaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageIndaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Indaptus Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.28% of the float of Indaptus Therapeutics has been sold short.Short Interest Ratio / Days to CoverIndaptus Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Indaptus Therapeutics has recently decreased by 35.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIndaptus Therapeutics does not currently pay a dividend.Dividend GrowthIndaptus Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INDP. Previous Next 2.8 News and Social Media Coverage News SentimentIndaptus Therapeutics has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Indaptus Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for INDP on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders29.50% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 7.06% of the stock of Indaptus Therapeutics is held by institutions.Read more about Indaptus Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Indaptus Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indaptus Therapeutics is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndaptus Therapeutics has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Indaptus Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About Indaptus Therapeutics Stock (NASDAQ:INDP)Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Read More INDP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INDP Stock News HeadlinesMay 31 at 2:14 AM | americanbankingnews.comIndaptus Therapeutics (NASDAQ:INDP) Trading Down 10.1%May 29, 2024 | finance.yahoo.comIndaptus Therapeutics to Present New Cohort Data Confirming Original “Pulse-Prime” Hypothesis Via Phase 1 Clinical Trial of Decoy20 at the American Society of Clinical Oncology Annual MeetingMay 22, 2024 | finance.yahoo.comIndaptus Therapeutics Announces Completion of First Patient to Receive Multiple Doses of Decoy20, the Company’s Broad-Based, “Pulse-Prime” Immuno-Oncology Therapy for Advanced Solid TumorsMay 8, 2024 | investorplace.comINDP Stock Earnings: Indaptus Therapeutics Misses EPS for Q1 2024May 8, 2024 | globenewswire.comIndaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Indaptus Therapeutics Amidst Promising Clinical Advances and Potential Market ImpactApril 12, 2024 | investing.comIndaptus reveals immune-boosting cancer therapy dataApril 12, 2024 | markets.businessinsider.comBuy Rating for Indaptus Therapeutics: Promising Oncology Breakthrough with Decoy20 PlatformApril 11, 2024 | globenewswire.comIndaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual MeetingMarch 28, 2024 | msn.comArmaguard rebuffs $26m cash lifelineMarch 28, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the MedInvest Biotech and Pharma Investor ConferenceMarch 25, 2024 | globenewswire.comIndaptus Therapeutics Previews Positive Mechanism of Action Data to be Presented at the American Association for Cancer Research Annual MeetingMarch 18, 2024 | finance.yahoo.comIndaptus Therapeutics to Participate in Tribe Public Webinar On Wednesday, March 20, 2024March 13, 2024 | msn.comIndaptus Dives on Quarterly ResultsMarch 13, 2024 | benzinga.comIndaptus Therapeutics: Q4 Earnings InsightsMarch 13, 2024 | globenewswire.comIndaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateMarch 4, 2024 | markets.businessinsider.comIndaptus Reports Positive Decoy20 Results, To Advance To Multi-dosing; Stock Up In Pre-marketMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortMarch 4, 2024 | globenewswire.comIndaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose CohortFebruary 25, 2024 | benzinga.comIndaptus Therapeutics Stock (NASDAQ:INDP) Insider TradesFebruary 15, 2024 | finance.yahoo.comIndaptus Therapeutics to Present at the 2024 BIO CEO & Investor ConferenceFebruary 8, 2024 | finance.yahoo.comIndaptus Therapeutics Expands Digital Presence with Launch of Social Media ChannelsJanuary 4, 2024 | finance.yahoo.comEuropean Patent Office Approves Key Patent for Indaptus Therapeutics’ Platform TechnologyDecember 22, 2023 | finance.yahoo.comIndaptus Therapeutics, Inc. (INDP) stock forecast and price targetNovember 27, 2023 | msn.comIndaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20See More Headlines Receive INDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/02/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INDP CUSIPN/A CIK1857044 Webintecpharma.com Phone(646) 427-2727Fax972-2586-9176Employees7Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+406.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-15,420,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-108.14% Return on Assets-92.86% Debt Debt-to-Equity RatioN/A Current Ratio6.70 Quick Ratio6.70 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book2.15Miscellaneous Outstanding Shares8,540,000Free Float6,020,000Market Cap$20.24 million OptionableNot Optionable Beta1.28 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Jeffrey A. Meckler (Age 57)CEO & Director Comp: $867.03kDr. Michael J. Newman Ph.D. (Age 68)Founder, Chief Scientific Officer & Director Comp: $659.99kMr. Walt Addison Linscott Esq. (Age 63)Chief Operating Officer Comp: $716.35kMr. Nir Sassi (Age 48)CFO, Secretary & Treasurer Comp: $378.47kDr. Roger J. Waltzman M.B.A. (Age 56)M.D., Chief Medical Officer Key CompetitorsHillstream BioPharmaNASDAQ:HILSBenitec BiopharmaNASDAQ:BNTCSELLAS Life Sciences GroupNASDAQ:SLSAnixa BiosciencesNASDAQ:ANIXCue BiopharmaNASDAQ:CUEView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 14,232 shares on 5/20/2024Ownership: 0.167%Glen R AndersonBought 23,934 shares on 8/14/2023Total: $56,005.56 ($2.34/share)Glen R AndersonBought 44,354 shares on 8/10/2023Total: $86,046.76 ($1.94/share)View All Insider TransactionsView All Institutional Transactions INDP Stock Analysis - Frequently Asked Questions Should I buy or sell Indaptus Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Indaptus Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" INDP shares. View INDP analyst ratings or view top-rated stocks. What is Indaptus Therapeutics' stock price target for 2024? 1 Wall Street research analysts have issued 12 month price objectives for Indaptus Therapeutics' shares. Their INDP share price targets range from $12.00 to $12.00. On average, they predict the company's share price to reach $12.00 in the next year. This suggests a possible upside of 406.3% from the stock's current price. View analysts price targets for INDP or view top-rated stocks among Wall Street analysts. How have INDP shares performed in 2024? Indaptus Therapeutics' stock was trading at $1.76 at the beginning of 2024. Since then, INDP stock has increased by 34.7% and is now trading at $2.37. View the best growth stocks for 2024 here. Are investors shorting Indaptus Therapeutics? Indaptus Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 16,600 shares, a decrease of 35.7% from the April 30th total of 25,800 shares. Based on an average daily trading volume, of 85,800 shares, the short-interest ratio is presently 0.2 days. Approximately 0.3% of the company's stock are short sold. View Indaptus Therapeutics' Short Interest. When is Indaptus Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our INDP earnings forecast. How were Indaptus Therapeutics' earnings last quarter? Indaptus Therapeutics, Inc. (NASDAQ:INDP) announced its earnings results on Wednesday, May, 8th. The company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.57) by $0.12. Who are Indaptus Therapeutics' major shareholders? Indaptus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Virtu Financial LLC (0.17%). Insiders that own company stock include Boyan Vesselinov Litchev, Glen R Anderson, Jeffrey A Meckler, Michael James Newman and Walt Addison Linscott. View institutional ownership trends. How do I buy shares of Indaptus Therapeutics? Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INDP) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsWrite this ticker symbol down…StocksToTradeTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBill Clinton Backing Biden Replacement???The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
